Highlights
- Approximately two-thirds of surveyed community pharmacies in British Columbia dispensed mifepristone within 3 days, with an additional 12% providing valid referrals, facilitating access to medication abortion.
- Despite near-universal geographic coverage where 99% of reproductive-aged females lived within 15-minute driving distance of a dispensing pharmacy, 23% of pharmacies neither dispensed mifepristone timely nor provided referrals, posing persistent access challenges.
- Urban pharmacies were paradoxically more likely to not dispense or refer compared to rural pharmacies, indicating systemic or operational barriers despite higher population densities.
- Socio-demographic factors such as residential instability and ethnocultural diversity correlated with poorer local availability, underscoring equity considerations in mifepristone access strategies.
Background
The introduction of mifepristone-misoprostol as a medication abortion regimen marked a transformative advance in reproductive healthcare, particularly following its regulatory approval in Canada in 2017 as a routinely prescribed medication without special restrictions. This policy shift aimed to reduce barriers to access, given medication abortion’s time-sensitive nature and critical role in safe abortion care. Despite enthusiastic adoption, anecdotal reports indicated patients experienced difficulties procuring mifepristone promptly from community pharmacies, highlighting an important gap between authorization and practical availability.
Access to timely medication abortion is essential given gestational limits and patient preferences, and community pharmacies represent a key distribution point. Understanding the availability of mifepristone within routine prescription frameworks can illuminate barriers and inform policy interventions to improve patient-centered care delivery.
Key Content
Study Design and Methodology
A population-based cross-sectional study conducted in British Columbia between July and August 2024 employed a mystery caller approach to quantify mifepristone availability in routine pharmacy practice. Surveyors impersonated patients with prescriptions requesting medication pickup within 3 calendar days, a clinically relevant timeframe for medication abortion initiation. In cases where pharmacies could not dispense within 3 days, referral practices were assessed.
The primary outcomes included the proportion of pharmacies providing timely dispensing or valid referrals and the geographic accessibility modeled by walking and driving distance catchments. This methodological approach robustly captured real-world access behaviors rather than relying solely on pharmacy self-report or registry data.
Availability and Referral Patterns
Among 1460 assessed pharmacies, 66% dispensed mifepristone promptly, with an additional 12% providing valid referrals, totalling 78% facilitating access to the medication either directly or indirectly. However, nearly a quarter (23%) neither dispensed the medication within 3 days nor referred patients, effectively placing the responsibility on patients to identify access points, which is burdensome and potentially delays care.
Referral efficacy was suboptimal; only one-third of nondispensing pharmacies referred patients to dispensing sites, indicating a fragmented pharmacy network for medication abortion. Such referral gaps may stem from knowledge deficits, stigma, or operational challenges.
Geographic Coverage and Socio-Demographic Disparities
Geospatial analyses demonstrated near-universal access within a 15-minute driving radius, with 99% of reproductive-aged females residing in such proximity. Yet, urban pharmacies paradoxically exhibited higher rates of non-dispensation and non-referral (RR 1.78) and were less likely to offer same-day dispensing (RR 0.39) compared to rural counterparts, a finding possibly reflecting heightened stigma, staffing practices, or commercial considerations in urban areas.
Moreover, areas characterized by higher residential instability and greater ethnocultural diversity experienced poorer local availability, signifying systemic inequities. These findings stress the need to contextualize pharmacy access within broader social determinants, guiding targeted interventions.
Comparison with International Contexts
Globally, accessibility to medication abortion via pharmacies varies widely, influenced by regulatory frameworks, provider attitudes, and healthcare infrastructure. The Canadian model of routine prescription regulation, as exemplified in this study, offers an informative case for jurisdictions seeking to expand safe, pharmacist-mediated abortion access. However, the observed dispensing and referral gaps underscore challenges beyond regulation, including provider education, anti-stigma efforts, and integration of clear referral pathways.
Expert Commentary
This study sheds light on tangible implementation barriers after the deregulation of mifepristone in a high-resource setting, moving beyond legislative success to probe practical access issues. The use of mystery callers captures patient experience authentically and highlights that authorization alone does not guarantee equitable distribution.
The elevated non-dispensation in urban pharmacies suggests that stigma and operational refusal—whether ethical or logistic—remain influential despite regulatory permissiveness. Urban pharmacy environments may be more complex, facing variable demand, staff attitudes, or corporate policies that impact dispensing behaviors.
Referral system deficiencies reveal structural gaps; protocols to ensure streamlined interpharmacy cooperation are underdeveloped and could be enhanced through digital networks or pharmacist training.
Furthermore, the correlation of mifepristone availability with ethnocultural diversity and residential instability emphasizes that equitable abortion care must address intersecting social vulnerabilities. Pharmacy access reflects broader health equity challenges and should be integrated with community outreach and culturally sensitive services.
These findings align with World Health Organization (WHO) recommendations advocating for expanded community-based access to medication abortion and the role of pharmacists as critical healthcare providers. Nonetheless, effective implementation requires addressing stigma, knowledge gaps, and creating supportive health system linkages.
Conclusion
The transition to routine prescription regulation for mifepristone in British Columbia has significantly increased geographic availability, benefiting 99% of reproductive-aged women within practical travel distances. Yet, a substantial minority of pharmacies do not dispense or refer, revealing persistent barriers that risk delaying or limiting patient access to timely medication abortion.
Policy and practice initiatives should prioritize pharmacist education, stigma reduction, and development of formal referral networks to mitigate identified gaps. Equitable access demands targeted attention to socio-demographic disparities, particularly in diverse and residentially unstable communities.
This study provides an evidence-based blueprint for other jurisdictions considering routine prescription frameworks for medication abortion, underscoring the necessity of coupling policy change with pragmatic access strategies to fulfill the promise of safe and timely abortion care.
References
- Nethery E, Xu C, Chan CSY, et al. Mifepristone Access Through Community Pharmacies When Regulated as a Routine Prescription Medication. JAMA Netw Open. 2025;8(11):e2542096. doi:10.1001/jamanetworkopen.2025.42096 IF: 9.7 Q1 . PMID: 41196594 IF: 9.7 Q1 ; PMCID: PMC12593126 IF: 9.7 Q1 .
- World Health Organization. Medical management of abortion. 2nd edition. Geneva: WHO; 2018. PMID: 30531283 IF: 1.0 Q3 .
- Grossman D, Grindlay K. Safety of medical abortion provided through telemedicine compared with in person. Obstet Gynecol. 2017;130(4):778-782. doi:10.1097/AOG.0000000000002235 IF: 4.7 Q1 . PMID: 28817127 IF: 1.1 Q3 .
- Brandi K, Kerns J, Hessini L. Abortion stigma: a reconceptualization of constituents, causes, and consequences. Womens Health Issues. 2021;31(1):28-36. doi:10.1016/j.whi.2020.10.008 . PMID: 33177358 IF: 6.4 Q1 .